| Autor: |
Guzek A; Department of Medical Diagnostics, Military Institute of Medicine, Warsaw, Poland., Korzeniewski K; Department of Epidemiology and Tropical Medicine, Military Institute of Medicine, 128 Szaserów Street, 04-141, Warsaw, Poland. kktropmed@wp.pl., Tomaszewski D; Clinic of Anesthesiology and Intensive Care, Military Institute of Medicine, Warsaw, Poland., Rybicki Z; Clinic of Anesthesiology and Intensive Care, Military Institute of Medicine, Warsaw, Poland., Zwolińska E; Department of Gynecology, Holy Family Maternity Hospital, Warsaw, Poland. |
| Abstrakt: |
The article presents the results of 11-year study (2005-2015) of Gram-negative bacteria responsible for pneumonia in 2033 mechanically ventilated patients hospitalized in Intensive Care Unit. Of 8796 biological samples, consisting mainly of bronchial aspirate (97.9 %), 2056 bacterial strains were isolated and subjected to identification. VITEK 2 was used to determine drug susceptibility (classified according to the EUCAST criteria). ESBL, MBL and KPC-producing strains were identified by means of phenotypic methods using appropriate discs. The findings were that the predominant bacteria responsible for infections consisted of Enterobacteriaceae (42.0 %), Acinetobacter baumannii (37.2 %), Pseudomonas aeruginosa (16.1 %), and Stenotrophomonas maltophila (4.7 %). We observed a rise in the number of bacteria causing pneumonia throughout the study period, especially in S. maltophila and Enterobacteriaceae ESBL (+). Gram-negative bacilli were 100 % susceptible to colistin, apart from naturally resistant strains such as Proteus mirabilis, Serratia marcescens, whereas Enterobacteriaceae ESBL (+) were susceptible to imipenem and meropenem. Acinetobacter baumannii strains exhibited the lowest drug susceptibility. In conclusion, we report an increase in the prevalence of pneumonia associated with Gram-negative bacteria in mechanically ventilated intensive care patients. Colistin remains the most effective drug against the majority of Gram-negative bacteria. Therapeutic problems are common in the course of treatment of Acinetobacter baumannii infections. |
